STK-001 Seen to Reduce Seizures in Children With Severe Dravet

STK-001 Seen to Reduce Seizures in Children With Severe Dravet

314723

STK-001 Seen to Reduce Seizures in Children With Severe Dravet

Single and multiple doses of Stoke Therapeutics’ investigational therapy STK-001 were well-tolerated and led to a significant reduction in the frequency of convulsive seizures among children and adolescents with Dravet syndrome in the first three months of follow-up, interim data from the ongoing Phase 1/2a MONARCH trial show. These findings are particularly promising since the patients enrolled have severe disease and almost all — 90.9% — were receiving at least three anti-seizure treatments. “Seeing an…

You must be logged in to read/download the full post.